



Sunday 23 October 2022

10:15–11:45	Pre-Congress Workshop: NEAT ID Symposium and Updates <i>Workshop organised by the NEAT ID Foundation</i>
	Welcome Christine Katlama , <i>Infectious Diseases, Sorbonne University, Paris, France</i> Carlo Giaquinto , <i>Paediatrics, University of Padova, Padova, Italy</i>
	Introduction Anton Pozniak , <i>Chelsea & Westminster Hospital, London, UK</i>
	NEAT ID background Stefano Vella , <i>Global Health, Catholic University of Rome, Rome, Italy</i>
	PrEP survey Jean-Michel Molina , <i>Infectious Diseases Department, Saint-Louis and Lariboisière Hospitals, and University of Paris, Paris, France</i>
	WISARD w48 data Stefano Rusconi , <i>Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy</i>
	PIONEER Marta Boffito , <i>Chelsea and Westminster Hospital and Imperial College London, London, UK</i>
	NEAT 22 sub studies: Weight gain Esteban Martinez , <i>Infectious Diseases, Hospital Clínic and University of Barcelona, Spain</i>
	NEAT ID studies and publications Georg Behrens , <i>Department for Clinical Immunology and Rheumatology Hannover Medical School, Hannover, Germany</i>
	NEAT ID new studies Stephane de Wit , <i>Infectious Diseases, Saint-Pierre University Hospital, Brussels, Belgium</i>
	NEAT ID integration grants Jürgen Rockstroh , <i>Department of Medicine, University of Bonn, Bonn, Germany</i>
	Closing remarks Anton Pozniak
10:15–12:15	STEPS 8I: A Community Initiative to Design the Pathway to a Long-Term Remission of HIV Infection <i>Workshop organised by the European AIDS Treatment Group (EATG)</i>
	Welcome and introduction Brian West , <i>EATG, Edinburgh, UK</i>
	Overview of HIV cure/remission research with different approaches Casper Rokx , <i>Erasmus University Medical Center and EHEG, Rotterdam, The Netherlands</i>
	Approaches to remission and European research in therapeutic vaccines Jean-Daniel Lelievre , <i>CHU Henri Mondor, Paris, France</i>
	Community perspective on cure/remission research Simon Collins , <i>HIV i-Base, London, UK</i>
	Q&A Session Moderator: Brian West
	Conclusion & follow up Brian West



Sunday 23 October 2022 (continued)

12:15–12:30	Coffee
12:30–13:30	Industry Symposium
13:30–14:15	Lunch
14:15–15:15	Industry Symposium
15:15–15:30	Coffee
15:30–16:30	Industry Symposium
16:30–17:15	Coffee
17:15–17:40	Official Opening
	Alexandra Calmy , Geneva University Hospitals, Geneva, Switzerland Chloe Orkin , Queen Mary University of London and Barts Health NHS Trust, London, UK
17:40–17:45	Welcome from Glasgow City
	Provost Jacqueline McLaren , Glasgow City Council, Glasgow, UK
17:45–19:15	HIV and Beyond: Planning the Unplanned – Keynote Lectures and Oral Papers
Chairs:	Alexandra Calmy , Geneva University Hospitals, Geneva, Switzerland Chloe Orkin , Queen Mary University of London and Barts Health NHS Trust, London, UK
17:45–18:15	Yazdan Yazdanpanah , Head of ANRS Emerging Infectious Diseases Agency, INSERM, Paris, France
18:15–18:30	Yana Panfilova , Founder, Union of Adolescents & Youth «Teenergizer», Kyiv, Ukraine
18:30–18:45	*O11: Clinical perspective on Ukrainian war refugee HIV care in Poland Milosz Parczewski , Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, Szczecin, Poland
18:45–19:00	*O12: New challenges of PrEP implementation during Russian-Ukrainian war Anna Koval , HIV Department, Public Health Center of the Ministry of Health of Ukraine, Kyiv, Ukraine
19:00–19:15	Discussion All
19:15–20:15	Welcome reception



Monday 24 October 2022

08:30–09:45	Lessons Learned from Conflicts and Disasters Across the World <i>In collaboration with the Euroguidelines in Central and Eastern Europe (ECEE) Network Group</i>
Chairs:	Justyna Kowalska , <i>Medical University of Warsaw and HIV Out-Patient Clinic, Hospital for Infectious Diseases, Warsaw, Poland</i> Cristiana Oprea , <i>Clinical HIV Department, Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania</i>
08:30–08:45	Welcome and introduction Justyna Kowalska
08:35–08:45	HIV services and internally displaced populations during war: Example from Ukraine Sergii Antoniak , <i>Gromashevsky Institute of Epidemiology and Infectious Diseases, Kyiv, Ukraine</i>
08:45–08:55	Syrian refugees in Turkey: Integrating migrants Deniz Gökengin , <i>Ege University, Izmir, Turkey</i>
08:55–09:05	Population in motion and access to care: Examples from Latin America Claudia Cortes , <i>University of Chile, Santiago, Chile</i>
09:05–09:15	Local ID outbreaks and disruption of HIV services: An example from Africa Louise Fortes , <i>Fann National University Hospital, Dakar, Senegal</i>
09:15–09:25	The Afghanistan experience: When the curtain drops Nilofar Ayoubi , <i>Women's Political Participation Network, Poland</i>
09:25–09:45	Panel discussion, Q&A and close All , joined by Teymur Noori , <i>European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden</i>
09:45–10:15	Scientific posters and coffee
10:15–11:15	HIV and Sexual Health
Chair:	Manuel Battegay , <i>Infectious Diseases and Internal Medicine, University Hospital, Basel, Switzerland</i>
10:15–10:30	New vaccines and DoxyPEP for sexually transmitted infections Jean-Michel Molina , <i>Infectious Diseases Department, Saint-Louis and Lariboisière Hospitals, and University of Paris, Paris, France</i>
10:30–10:45	ChemSex/stimulant use and intersection with HIV care Jean-Victor Blanc , <i>Department of Psychiatry, Hôpital Saint Antoine, Paris, France</i>
10:45–11:00	*O21: Laboratory analysis of HIV infections in the year 1 unblinded period of HPTN 083: Injectable cabotegravir for PrEP in MSM and TGW* Raphael Landovitz , <i>Medicine, University of California, Los Angeles, CA, USA</i>
11:00–11:15	Discussion All



Monday 24 October 2022 (continued)

11:15–12:45	HIV Clinical Challenges (I)
Chairs:	Andrew Carr , <i>HIV, Immunology and Infectious Diseases Unit, St Vincent's Hospital, Sydney, Australia</i> Nesrine Rizk , <i>Department of Internal Medicine, American University of Beirut, Beirut, Lebanon</i>
11:15–11:35	Fatty liver disease Patrick Ingiliz , <i>Hepatology, Henri-Mondor University Hospital, Paris, France</i>
11:35–11:55	Inflammation and HIV: A long history – what do we really know? Patrick Mallon , <i>School of Medicine, University College Dublin, and Infectious Diseases Unit, St Vincent's University Hospital, Dublin, Ireland</i>
11:55–12:10	*O22: Use of preventive measures for cardiovascular disease in people living with HIV Nadine Jaschinski , <i>CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark</i>
12:10–12:30	Advances in treatment and prevention of tuberculosis: A new paradigm? Maryline Bonnet , <i>TransVIH MI Research Unit, Institut de Recherche pour le Développement, Université de Montpellier, Inserm, Montpellier, France.</i>
12:30–12:45	*O23: Risk of tuberculosis after initiation of antiretroviral therapy among people living with HIV in Europe Isik Somuncu Johansen , <i>Department of Infectious Diseases, Odense University Hospital, Odense, Denmark</i>
12:45–14:00	Scientific posters and lunch
13:00–14:00	Industry Symposium
14:00–15:00	Beyond Clinical Trials: Prescribing for Complex Populations – Interactive Case Study Session <i>In collaboration with the University of Liverpool website: www.hiv-druginteractions.org</i>
Chairs:	Saye Khoo , <i>Department of Pharmacology, University of Liverpool, Liverpool, UK</i> Fiona Marra , <i>Pharmacy Department, Infections Disease, Greater Glasgow and Clyde NHS, Glasgow, UK</i> Catia Marzolini , <i>University Hospital of Basel, Basel, Switzerland, and University of Liverpool Drug-Drug Interactions Websites, Liverpool, UK</i>
14:00–14:05	Introduction Saye Khoo, Fiona Marra, Catia Marzolini
14:05–14:17	Gender transitioning Kate Nambiar , <i>Welsh Gender Service, Cardiff & Vale University Health Board, St David's Hospital, Cardiff, UK</i>
14:17–14:29	Menopause Melanie Nicol , <i>Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, MN, USA</i>
14:29–14:41	GI surgery Angela Colbers , <i>Radboud University Medical Centre, Nijmegen, The Netherlands</i>
14:41–15:00	Panel discussion, Q&A and close All



Monday 24 October 2022 (continued)

15:00–15:45	Advances in Treatment of Cryptococcal Meningitis The Joep Lange and Jacqueline van Tongeren Memorial Lecture
15:00–15:05	Introduction <i>Lecture dedicated to Joep Lange and Jacqueline van Tongeren in recognition of their commitment and passion to rid the world of HIV/AIDS</i> Peter Reiss , <i>Global Health, Amsterdam UMC, University of Amsterdam; and Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands</i>
15:05–15:30	Advances in Treatment of Cryptococcal Meningitis Joseph Jarvis , <i>Tropical Medicine and International Health, London School of Hygiene and Tropical Medicine, Gaborone, Botswana</i>
15:30–15:45	Discussion
15:45–17:15	The Evidence for Same Day ARV Therapy <i>In collaboration with the British HIV Association (BHIVA)</i>
Chairs:	Caroline Sabin , <i>Medical Statistics and Epidemiology at University College London (UCL), London, UK</i> Alex Sparrowhawk , <i>Terrence Higgins Trust, London, UK</i>
15:45–15:50	Welcome and introduction Caroline Sabin
15:50–16:05	The evidence for early treatment in the context of primary infection Sarah Fidler , <i>Department of Infectious Diseases, Imperial College London, London, UK</i>
16:05–16:20	Same day ART in high income settings Laura Waters , <i>Mortimer Market Centre, University College London Hospitals NHS Foundation Trust; and Chair, BHIVA</i>
16:20–16:35	Same day ART in low- and middle-income settings Bernhard Kerschberger , <i>Head of Mission, Médecins Sans Frontières (MSF), Eswatini</i>
16:35–16:45	Community perspective Alex Sparrowhawk
16:45–16:55	*O24: Rapid ART initiation using BIC/FTC/TAF and TDF+3TC+EFV in people with HIV in China: A randomised control trial Lili Dai , <i>Youan Hospital, No. 8, West Toutiao, Fengtai District, Beijing, China</i>
16:55–17:15	Discussion All
17:15–17:30	Scientific posters and coffee
17:30–19:00	Industry Symposium



Tuesday 25 October 2022

08:30–09:30	Industry Symposium
09:30–09:45	Scientific posters and coffee
09:45–11:00	Access to Long-Acting Prevention for Key Populations in Low and Middle Income Countries (LMICs): Making it Work <i>In collaboration with the International AIDS Society (IAS)</i>
Chairs:	Claudia Cortes , University of Chile, Santiago, Chile; IAS Governing Council Anton Pozniak , Chelsea & Westminster Hospital, London, UK; Immediate Past President, International AIDS Society
09:45–09:50	Introduction and aims Anton Pozniak and Claudia Cortes
09:50–10:02	Landscape, service delivery, and pathways to affordability and access Mitchell Warren , AIDS Vaccine Advocacy Coalition (AVAC), New York, NY, USA
10:02–10:14	Examples and insights from Asia Nittaya Phanuphak , Institute of HIV Research and Innovation, Bangkok, Thailand
10:14–10:26	Examples and insights from Latin America Beatriz Grinsztejn , FioCruz, Rio de Janeiro, Brazil
10:26–10:38	Examples and insights from Africa Kenly Sikwese , AfroCAB, Lusaka, Zambia
10:38–10:55	Panel discussion and Q&A All , joined by Cissy Kityo , Joint Clinical Research Centre, Kampala, Uganda
10:55–11:00	Summary and close Chairs
11:00–11:45	HIV Clinical Challenges (II)
Chairs:	Rak Nandwani , Board of Public Health, Scotland, and Glasgow Caledonian Hospital, Glasgow, UK Lene Ryom , Department of Infectious Diseases, Hvidovre University Hospital, and CHIP, Center of Excellence for Health, Immunity and Infections, Rigshospitalet, Copenhagen, Denmark
11:00–11:15	*O31: Older people with well-controlled HIV have similar antibody and higher T-cell responses after vaccination against SARS-CoV-2 compared to demographically and lifestyle-comparable people without HIV Myrthe Verburgh , Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
11:15–11:30	*O32: External validation of the Dat'AIDS score for predicting 5-year mortality among elderly patients living with HIV in the Swiss HIV Cohort Study Maxime Hentzien , HIV/AIDS Research Unit, Geneva University Hospitals, Geneva, Switzerland
11:30–11:45	*O33: COCOVIH study: Impact of comorbidities on the over-mortality of people living with HIV François PrevotEAU Du Clary , Centre de Santé Sexuelle, La Grave Hospital, University Hospital Toulouse, Toulouse, France



Tuesday 25 October 2022 (continued)

11:45–12:30	Lock Lecture <i>HIV Glasgow is honoured to have been chosen by the Royal College of Physicians and Surgeons of Glasgow to present the Lock Lecture as part of the Scientific Programme</i>
11:45–11:50	Lock Lecture: Introduction
11:50–12:20	PrEP vs PEP Interface: Where are We Now? <i>Sheena McCormack, Clinical Epidemiology, Imperial College London, UK</i>
12:20–12:30	Q&A
12:30–13:45	Scientific posters and lunch
12:45–13:45	Industry Symposium
13:45–15:00	Response to Emerging Problems <i>In collaboration with the European AIDS Clinical Society (EACS)</i>
Chairs:	<i>Tristan Barber, HIV Medicine, Ian Charleson Day Centre, Royal Free Hospital, London, UK; and Chair, EACS Young Investigators (YING)</i> <i>Georg Behrens, Department for Clinical Immunology and Rheumatology Hannover Medical School, Hannover, Germany; and Co-Chair, EACS Guidelines Group</i>
13:45–13:50	Welcome and introductions Chairs
13:50–14:05	Unified Support Framework to Support HIV Cascade of Care for Displaced Persons in Europe <i>Marta Vasylyev, Infectious Diseases, Astar Medical Center, Lviv, Ukraine; and WAVE</i>
14:05–14:20	HIV Clinics and people living with HIV In times of epidemics: Impact of COVID-19 and monkeypox <i>Casper Rokx, HIV/Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands; and YING</i>
14:20–14:35	2022 update EACS Guidelines <i>Juan Ambrosioni, HIV/AIDS Unit and Infectious Disease Service, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain; and EACS Guidelines Group</i>
14:35–14:55	Panel discussion and Q&A All
14:55–15:00	Wrap up and close
15:00–16:00	Novel Therapeutics
Chairs:	<i>Pedro Cahn, Fundación Huésped, Buenos Aires, Argentina</i> <i>Claudia Estcourt, Glasgow Caledonian University, Glasgow, UK</i>
15:00–15:25	HIV and COVID-19 drug development: Lessons learned for the next pandemic <i>Daniel Kuritzkes, Division of Infectious Diseases at Brigham and Women's Hospital, Boston, MA, USA</i>
15:25–15:45	bNABS for HIV <i>Marina Caskey, Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA</i>



Tuesday 25 October 2022 (continued)

15:00–16:00	Novel Therapeutics (continued)
15:45–16:00	*O34: VH3810109 (N6LS) reduces viremia across a range of doses in ART-naive adults living with HIV: Proof of concept achieved in the phase IIa BANNER (207959, NCT04871113) study † Peter Leone , <i>Clinical Development, ViiV Healthcare, Durham, NC, USA</i>
16:00–17:15	HIV Current Case Challenges: Interactive Case Study Session <i>In collaboration with the International Antiviral Society-USA (IAS-USA)</i>
Chairs:	Roy Gulick , <i>Infectious Diseases, Weill Cornell Medicine, New York, NY, USA</i> Chloe Orkin , <i>Queen Mary University of London and Barts Health NHS Trust, London, UK</i>
16:00–16:05	Welcome and Introductions Roy Gulick
16:05–16:25	Heavily treatment-experienced case Alexandra Calmy , <i>Geneva University Hospitals, Geneva, Switzerland</i>
16:25–16:45	HPV-related case Deborah Konopnicki , <i>Department of Infectious Diseases, Saint-Pierre University Hospital, Paris, France and Université Libre de Bruxelles, Brussels, Belgium</i>
16:45–17:05	HIV and COVID-related case Jose Arribas , <i>La Paz Hospital, Madrid, Spain</i>
17:05–17:15	Key learnings summary and close All
17.15–17.30	Scientific posters and coffee
17:30–18:30	Industry Symposium

*Refer to end of programme for full author list for oral abstracts

†Industry Speakers presenting are not in accordance with the EACCME rules. Therefore, the EACCME is unable to grant credit for these specific presentations.



Wednesday 26 October 2022

08:30–09:30	Ageing with HIV: From Knowledge to Action <i>In collaboration with the European AIDS Treatment Group (EATG)</i>
Chairs:	Mario Cascio , <i>European AIDS Treatment Group (EATG), Italy</i> Maryan Said , <i>EATG, Oslo, Norway</i>
08:30–08:34	Welcome and introduction Maryan Said
08:34–08:55	Community and clinical perspectives Axel Vanderperre , <i>UTOPIA_BXL, Brussels, Belgium</i> Rebecca Mbewe , <i>Positively UK, London, UK</i> Giovanni Guaraldi , <i>Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy</i>
08:55–09:15	How to move forward: Panel discussion and Q&A Moderated by Brian West , <i>EATG, Edinburgh, Scotland</i> , joined by Axel Vanderperre , Rebecca Mbewe , Giovanni Guaraldi , Maka Gogia , <i>EATG, Tblisi, Georgia</i> , and Esteban Martinez , <i>Infectious Diseases, Hospital Clínic and University of Barcelona, Spain</i>
09:15–09:20	Wrap up and summary remarks Anton Basenko , <i>Global Fund Advocates Network, Brussels, Belgium</i>
09:20–09:30	Call to action: The Glasgow Manifesto Mario Cascio
09:30–10:30	Mini Oral Session
Chairs:	Karine Lacombe , <i>Hôpital Saint Antoine, Paris, France</i> Kim Sigaloff , <i>Internal Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands</i>
09:30–09:40	*MO41: Durable efficacy of switching from a three-/four-drug tenofovir alafenamide (TAF)-based regimen to the two-drug regimen dolutegravir/lamivudine (DTG/3TC) in the TANGO study through week 196 Jean-Paul Routy , <i>Infectious Diseases, McGill University Health Centre, Montreal, Canada</i>
09:40–09:50	*MO42: Impact of switch towards 3TC/dolutegravir on the intact and total viral reservoir in the Rumba study Linos Vandekerckhove , <i>Department of Internal Medicine and Pediatrics, HIV Cure Research Center, Ghent University, Ghent, Belgium</i>
09:50–10:00	*MO43: Prevalence, risk factors and the impact of antiretroviral treatment in SARS-CoV-2 infection in people with HIV: A cross-sectional study Jose M Miro , <i>HIV Unit, Infectious Diseases Service, Hospital Clinic - August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain</i>
10:00–10:10	*MO44: Prevalence, outcomes, and factors associated with testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among people living with HIV across Europe in the multinational EuroSIDA cohort Wendy Bannister , <i>Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, Copenhagen, Denmark</i>



Wednesday 26 October 2022 (continued)

09:30–10:30	Mini Oral Session (continued)
10:10–10:20	*MO45: The stability and predictors of change in clinically relevant multimorbidity clusters over time among people with HIV in the Pharmacokinetic and clinical Observations in PeoPlE over fifty (POPPY) study <i>Luxsena Sukumaran, Infection & Population Health, University College London, London, UK</i>
10:20–10:30	*MO46: Trends in maternal characteristics and pregnancy outcomes among women living with HIV in the UK: 2014 to 2019 <i>Helen Peters, UCL Great Ormond Street Institute of Child Health, Integrated Screening Outcomes Surveillance Service, London, UK</i>
10:30–11:00	Scientific posters and coffee
11:00–12:15	Monkeypox: Where Are We Now and What Have We Learned?
Chairs:	<i>Alexandra Calmy, Geneva University Hospitals, Geneva, Switzerland</i> <i>Simon Collins, HIV i-base, London, UK</i>
11:00–11:05	Introduction <i>Alexandra Calmy</i>
11:05–11:10	Epidemiology of monkeypox and public health response <i>Teymur Noori, European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden</i>
11:10–11:25	Case definitions, evolution and HIV presentation <i>Chloe Orkin, Queen Mary University of London and Barts Health NHS Trust, London, UK</i>
11:25–11:40	Treatment, vaccines and guidelines <i>Sanjay Bhagani, Infectious Diseases/HIV Medicine, Royal Free London Foundation Trust, Research Department of Infection, UCL, London, UK; President, European AIDS Clinical Society (EACS)</i>
11:40–11:50	The patient perspective <i>Harun Tulunay, HIV, sexual health and mental health advocate; Training and Volunteer Co-ordinator, Positively UK, London, UK</i>
11:50–12:05	*O41A: Perceptions and understandings of media and public health messaging about the monkeypox outbreak in the UK: Findings from a rapid response, co-produced survey and *O41B: Including women in the public health response to the monkeypox (MPXV) outbreak in the UK: Findings from a rapid response, co-produced survey <i>Sara Paparini, Wolfson Institute of Population Health and SHARE Collaborative, Queen Mary University of London, London, UK</i>
12:05–12:15	Panel discussion, Q&A and close All
12:15–13:30	Late Breakers / Hot Topics
Chairs:	<i>Linda Gail-Bekker, The Desmond Tutu HIV Centre, University of Cape Town, South Africa</i> <i>Ian Williams, University College London Medical School, London, UK</i>
12:15–12:30	O42: Virological failure and HIV RNA re-suppression rates in four randomised trials of dolutegravir, efavirenz or protease inhibitor-based treatment in 3116 participants <i>Andrew Hill, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK</i>



Wednesday 26 October 2022 (continued)

12:15–13:30	Late Breakers / Hot Topics (continued)
12:30–12:45	<p>*O43: Six-month outcomes of every 2-months long-acting cabotegravir and rilpivirine in a real-world setting: Effectiveness, adherence to injections and patient-reported outcomes from PLWHIV in the German CARLOS cohort Celia Jonsson-Oldenbüttel, <i>Clinical Care, Medizinisches Versorgungszentrum München am Goetheplatz, Munich, Germany</i></p>
12:45–13:00	<p>*O44: Expanded multivariable models to assist patient selection for long-acting cabotegravir+rilpivirine treatment: Clinical utility of a combination of patient, drug concentration, and viral factors associated with virological failure over 152 weeks Chloe Orkin, <i>Queen Mary University of London and Barts Health NHS Trust, London, UK</i></p>
13:00–13:15	<p>*O45: Modeling and simulation to optimize islatravir doses in HIV treatment naïve and virologically suppressed populations †Ryan Vargo, <i>Merck & Co., Inc., Rahway, NJ, USA</i></p>
13:15–13:30	<p>*O46: Total lymphocyte and CD4+ T-cell count changes in participants receiving islatravir (0.25, 0.75 and 2.25 mg QD) and doravirine +/- lamivudine: post-hoc analysis from a phase 2b dose-ranging study (P011) †Todd Correll, <i>Merck & Co., Inc., Rahway, NJ, USA</i></p>
13:30–13:35	Closing remarks
	<p>Alexandra Calmy, <i>Geneva University Hospitals, Geneva, Switzerland</i> Chloe Orkin, <i>Queen Mary University of London and Barts Health NHS Trust, London, UK</i></p>
13:35	Lunch and depart

*Refer to end of programme for full author list for oral abstracts

†Industry Speakers presenting are not in accordance with the EACCME rules. Therefore, the EACCME is unable to grant credit for these specific presentations.



Oral Abstracts

Sunday 23 October 2022

O11: Clinical perspective on Ukrainian war refugee HIV care in Poland

Milosz Parczewski¹, Elzbieta Jablonowska², Kamila Wójcik-Cichy², Dmytro Zhyvytsia³, Magdalena Witak-Jedra³, Ewa Siwak⁴, Justyna Kowalska⁵, Anita Olczak⁶, Aleksandra Szymczak⁷, Monika Bogiaga-Jasik⁸, Anna Kalinowska-Nowak⁸, Pawel Jakubowski⁹, Maria Hlebowicz⁹, Blazej Rozplochowski¹⁰, Wladyslaw Lojewski¹¹, Kaja Scheibe¹, Karol Serwin¹

¹Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, Szczecin, Poland; ²Department of Infectious Diseases and Hepatology, Medical University of Łódź, Łódź, Poland; ³Infectious, Tropical Diseases and Immune Deficiency, Regional Hospital, Szczecin, Poland; ⁴Department of Infection, Tropical Diseases and Hepatology, Medical University in Warsaw, Warsaw, Poland; ⁵Department for Adult Infection Diseases, Medical University in Warsaw, Warsaw, Poland; ⁶Department of Infectious Diseases and Hepatology, Faculty of Medicine, Nicolaus Copernicus University Ludwik Rydygier Collegium, Bydgoszcz, Poland; ⁷Department of Infectious Diseases, Liver Disease and Acquired Immune Deficiencies, Wrocław Medical University, Wrocław, Poland; ⁸Department of Infectious and Tropical Diseases, Jagiellonian University Medical College, Kraków, Poland; ⁹Infectious Diseases, Pomeranian Center for Infectious Diseases and Tuberculosis, Gdansk, Poland; ¹⁰Department of Infectious Diseases, Hepatology and Acquired Immunodeficiencies, Karol Marcinkowski University of Medical Sciences, Poznan, Poland; ¹¹Department of Infectious Diseases, Regional Hospital in Zielona Gora, Zielona Góra, Poland

O12: New challenges of PrEP implementation during Russian-Ukrainian war

Anna Koval¹, Larysa Hetman¹, Serhii Riabokon¹, Andrii Bilets¹, Tetiana Koval²

¹HIV Department, Public Health Center of the Ministry of Health of Ukraine, Kyiv, Ukraine; ²Infectious Diseases, Poltava State Medical University, Poltava, Ukraine

Monday 24 October 2022

O21: Laboratory analysis of HIV infections in the year 1 unblinded period of HPTN 083: injectable cabotegravir for PrEP in MSM and TGW

Mark Marzinke¹, Beatriz Grinsztejn², Jessica Fogel¹, Estelle Piwowar-Mann¹, Brett Hanscom³, Zhe Wang⁴, Christos Petropoulos⁵, Elias Halvas⁶, John Mellors⁷, Peter Anderson⁸, Omar Sued⁹, Suwat Chariyalertsak¹⁰, Hyman Scott¹¹, Kenneth Mayer¹², Roberto Arduino¹³, Ryan Kofron¹⁴, Myron Cohen¹⁵, Marty St Clair¹⁶, Alex Rinehart¹⁷, James Rooney¹⁸, Adeola Adeyeye¹⁹, Marybeth McCauley²⁰, Susan Eshleman¹, **Raphael Landovitz**¹⁴

¹Medicine, Johns Hopkins University, Baltimore, MD, USA; ²Instituto de Pesquisa Clinica Evandro Chagas-Fiocruz, Rio de Janeiro, Brazil; ³Vaccine and Infectious Disease, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ⁴Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ⁵Research and Development, Labcorp, San Francisco, CA, USA; ⁶Medicine, University of Pittsburgh, Pittsburgh, PA, USA; ⁷Immunology, University of Pittsburgh, Pittsburgh, PA, USA; ⁸Pharmacy, University of Colorado, Aurora, CO, USA; ⁹Fundación Huésped, Buenos Aires, Argentina; ¹⁰Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand; ¹¹San Francisco Department of Public Health, San Francisco, CA, USA; ¹²Medicine, Harvard Medical School, Boston, MA, USA; ¹³Internal Medicine, McGovern Medical School, Houston, TX, USA; ¹⁴Medicine, University of California, Los Angeles, Los Angeles, CA, USA; ¹⁵Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ¹⁶Virology, ViiV Healthcare, Durham, NC, USA; ¹⁷Global HIV Prevention Strategy, ViiV Healthcare, Durham, NC, USA; ¹⁸Medical Affairs, Gilead Sciences, San Mateo, CA, USA; ¹⁹Division of AIDS, National Institutes of Health, Bethesda, MD, USA; ²⁰FHI 360, Durham, NC, USA



Oral Abstracts (continued)

Monday 24 October 2022 (continued)

022: Use of preventive measures for cardiovascular disease in people living with HIV

Nadine Jaschinski¹, Bastian Neesgaard¹, Ferdinand Wit², Marc van der Valk³, Hyldrych F Günthard⁴, Marcel Stöckle⁵, Elmar Wallner⁶, Justyna Kowalska⁷, Anna Lisa Ridolfo⁸, Piotr Nowak⁹, Antonella Castagna¹⁰, Antonella d'Arminio Monforte¹¹, Nikoloz Chkhartishvili¹², Kathy Petoumenos¹³, Jennifer Hoy¹⁴, Harmony Garges¹⁵, Jim Rooney¹⁶, Lital Young¹⁷, Sean Hosein¹⁸, Jens D Lundgren¹, Lars Peters¹, Amanda Mcroft¹⁹, Lene Ryom²⁰

¹CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; ²AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort, Stichting HIV Monitoring, Amsterdam, Netherlands; ³AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort, Stichting HIV Monitoring; Amsterdam University Medical Centers, University of Amsterdam, Division of Infectious diseases, Amsterdam, Netherlands; ⁴Swiss HIV Cohort Study (SHCS), University of Zurich; University Hospital Zurich, Department of Infectious Diseases, University Hospital Zurich, Zurich, Switzerland; ⁵Swiss HIV Cohort Study (SHCS), University of Zurich, Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Basel, University of Basel, Basel, Switzerland; ⁶Department für Gastroenterologie, Infektiologie, Pneumologie, Landeskrankenhaus Graz II, Standort West, Graz, Austria; ⁷Infectious Diseases, Hospital for Infectious Diseases in Warsaw, Warsaw, Poland; ⁸III Infectious Diseases Unit, ASST Fatebenefratelli-Sacco, Milano, Italy; ⁹Swedish InfCare HIV Cohort, Karolinska University Hospital, Stockholm, Sweden; ¹⁰San Raffaele Scientific Institute, Università Vita-Salute San Raffaele, Milano, Italy; ¹¹Italian Cohort Naïve Antiretrovirals (ICONA), ASST Santi Paolo e Carlo, Milano, Italy; ¹²Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi Georgian National AIDS Health Information System (AIDS HIS), Georgia; ¹³The Australian HIV Observational Database (AHOD), UNSW, Sydney, Australia; ¹⁴HIV Medicine, The Alfred Hospital and Monash University, Melbourne, Australia; ¹⁵ViiV Healthcare, Research Triangle Park, Durham, NC, USA; ¹⁶Gilead Sciences, Foster City, CA, USA; ¹⁷Merck Sharp & Dohme, Kenilworth, NJ, USA; ¹⁸European AIDS Treatment Group (EATG), Brussels, Belgium; ¹⁹Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London; CHIP, Rigshospitalet, University of Copenhagen, London, UK; ²⁰Department of Infectious Diseases 144, CHIP, Rigshospitalet, University of Copenhagen, Hvidovre University Hospital, Copenhagen, Denmark

023: Risk of tuberculosis after initiation of antiretroviral therapy among people living with HIV in Europe

Isik Somuncu Johansen¹, Ashley Roen², Ole Kirk³

¹Department of Infectious Diseases, Odense University Hospital, Odense, Denmark; ²Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK; ³Centre of Excellence for Health, Immunity and Infections & Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, CHIP, Copenhagen, Denmark

024: Rapid ART initiation using BIC/FTC/TAF and TDF+3TC+EFV in people with HIV in China: A randomised control trial

Shiyun Lv, Lijun Sun, Wei Hua, Aixin Li, **Lili Dai**

Youan Hospital, No. 8, West Toutiao, Fengtai District, Beijing, China

Tuesday 25 October 2022

031: Older people with well-controlled HIV have similar antibody and higher T-cell responses after vaccination against SARS-CoV-2 compared to demographically and lifestyle-comparable people without HIV

Myrthe Verburgh¹, Lisa van Pul², Marloes Grobben³, Anders Boyd⁴, Ferdinand Wit¹, Ad van Nuenen², Karel van Dort², Khadija Tejjani³, Jacqueline van Rijswijk³, Margreet Bakker³, Lia van der Hoek³, Maarten Schim van der Loeff⁵, Marc van der Valk¹, Marit van Gils³, Neeltje Kootstra², Peter Reiss¹

¹Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; ²Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; ³Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands; ⁴Infectious Diseases, HIV Monitoring Foundation, Amsterdam, Netherlands; ⁵Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, Netherlands



Oral Abstracts (continued)

Tuesday 25 October 2022 (continued)

032: External validation of the Dat'AIDS score for predicting 5-year mortality among elderly people with HIV in the Swiss HIV Cohort Study

Maxime Hentzien¹, Jaromil Frossard¹, Roger Kouyos², Virginie Prendki³, José Damas⁴, Eveline Hofmann⁵, Dominique Braun⁶, Patrick Schmid⁷, Enos Bernasconi⁸, Silvio Ragozzino⁹, Orestis Efthimiou¹⁰, Cyrille Delpierre¹¹, Clotilde Allavena¹², Firouzé Bani-Sadr¹³, Alexandra Calmy¹

¹HIV/AIDS Research Unit, Geneva University Hospitals, Geneva, Switzerland; ²Institute of Medical Virology, University of Zurich, Zurich, Switzerland; ³Division of Internal Medicine for the Aged, Geneva University Hospitals, Geneva, Switzerland; ⁴Infectious Diseases Service, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland; ⁵Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland; ⁶Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; ⁷Division of Infectious Diseases, Cantonal Hospital St. Gallen, St. Gallen, Switzerland; ⁸Division of Infectious Diseases, Ospedale Regionale di Lugano (Ente Ospedaliero Cantonale) and University of Southern Switzerland, Lugano, Switzerland; ⁹Department of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland; ¹⁰Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland; ¹¹Unité mixte de recherche (UMR) 1027, Institut national de la santé et de la recherche médicale, Toulouse, France; ¹²Equipe d'accueil (EA) 1413, Institut national de la santé et de la recherche médicale (INSERM), Centre Hospitalier Universitaire, Infectious Diseases Department, Nantes, France; ¹³Department of Internal Medicine, Clinical Immunology and Infectious Diseases, Reims University Hospital, Reims, France

033: COCOVIH study: Impact of comorbidities on the over-mortality of people living with HIV

François PrevotEAU du Clary¹, Catherine Majerholc², David Zucman³, Jean Michel Livrozet⁴, Benjamin Guigui⁵, Alexandre Vallee⁶, Caroline Laurendeau⁷, Stephane Bouee⁷

¹Centre de Santé Sexuelle, La Grave Hospital, University Hospital Toulouse, Toulouse, France; ²Internal Medicine, University Hospital Toulouse, Toulouse, France; ³Internal Medicine, Foch Hospital, Suresnes, France; ⁴Service de Maladies Infectieuses et Tropicales, Edouard Herriot Hospital, Lyon, France; ⁵Department of General Medicine, Université Paris Cité, Paris, France; ⁶Department of Epidemiology, Data and Biostatistics, Foch Hospital, Suresnes, France; ⁷Public Health and Epidemiology, CEMKA-EVAL, Bourg La Reine, France

034: VH3810109 (N6LS) reduces viremia across a range of doses in ART-naive adults living with HIV: Proof of concept achieved in the phase IIa BANNER (207959, NCT04871113) study

Peter Leone¹, Alejandro Ferro², Charlotte-Paige Rolle³, Sergio Lupo⁴, Joseph McGowan⁵, Marina Klein⁶, Pedro Cahn⁷, Paul Benson⁸, Marisa Sanchez⁹, Christopher Bettacchi¹⁰, Stefan Schneider¹¹, Paul Wannamaker¹², Beta Win¹³, Judah Abberbock¹⁴, Mark Baker¹⁵, Viviana Wilches¹⁶, Darren Bentley¹⁷, Margaret Gartland¹², Max Lataillade¹⁸, Jan Losos¹⁹

¹Clinical Development, ViiV Healthcare, Durham, NC, USA; ²Infectious Diseases, Centro de Investigaciones Medicas, Mar del Plata, Argentina; ³Infectious Diseases, Orlando Immunology Center, Orlando, FL, USA; ⁴Infectious Diseases Centro de Asistencia e Investigación Clínica Integral (CAICI), Rosario, Argentina; ⁵Infectious Diseases, Northwell Health, New York, NY, USA; ⁶Infectious Diseases, McGill University Health Centre, Montreal, Quebec, Canada; ⁷Infectious Diseases, Fundacion Huesped, Buenos Aires, Argentina; ⁸Infectious Diseases, Be Well Medical Center, Berkley, MI, USA; ⁹Infectious Diseases, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; ¹⁰Infectious Diseases, North Texas Infectious Disease Consultants, Dallas, TX, USA; ¹¹Infectious Diseases, Long Beach Education and Research Consultants, Long Beach, CA, USA; ¹²Clinical Development, ViiV Healthcare, Research Triangle Park, NC, USA; ¹³Safety, Evaluation and Risk Management (SERM), GSK, Brentford, UK; ¹⁴Statistics, GSK, Upper Providence, PA, USA; ¹⁵Clinical Pharmacology, GSK, Brentford, UK; ¹⁶Clinical Development, GSK, Upper Providence, PA, USA; ¹⁷Clinical Pharmacology, Certara, Sheffield, UK; ¹⁸Global Research Strategy, ViiV Healthcare, Branford, CT, USA; ¹⁹Early Development, ViiV Healthcare, Durham, NC, USA



Oral Abstracts (continued)

Wednesday 26 October 2022

MO41: Durable efficacy of switching from a three-/four-drug tenofovir alafenamide (TAF)-based regimen to the two-drug regimen dolutegravir/lamivudine (DTG/3TC) in the TANGO study through week 196

Stéphane De Wit¹, Fabrice Bonnet², Olayemi Osiyemi³, Fiona Bisshop⁴, Julian Olalla⁵, Jean-Pierre Routy⁶, Christoph Wyen⁷, Riya Moodley⁸, Keith Pappa⁹, Ruolan Wang¹⁰, James Oyee¹¹, Parminder Saggu¹¹, Emilio Letang¹², Brian Wynne⁹, Bryn Jones¹³, Kimberly Smith¹⁴, Mounir Ait-Khaled⁸

¹Infectious Diseases, Centre Hospitalier Universitaire Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium; ²Infectious Diseases, Centre Hospitalier Universitaire de Bordeaux, Service de Médecine Interne et Maladies Infectieuses, Bordeaux, France; ³Infectious Diseases, Triple O Research Institute PA, West Palm Beach, FL, USA; ⁴Infectious Diseases, Holdsworth House Medical Brisbane, Queensland, Australia; ⁵Infectious Diseases, Unidad de Medicina Interna, Hospital Costa del Sol, Marbella, Spain; ⁶Infectious Diseases, McGill University Health Centre, Montreal, Canada; ⁷Infectious Diseases, Praxis am Ebertplatz, Cologne, Germany; ⁸Clinical Development, ViiV Healthcare, Brentford, UK; ⁹Clinical Development, ViiV Healthcare, Durham, NC, USA; ¹⁰Translation Medicine, ViiV Healthcare, Durham, NC, USA; ¹¹Statistics, GSK, Brentford, UK; ¹²Global Medical Affairs, ViiV Healthcare, Madrid, Spain; ¹³Global Medical Affairs, ViiV Healthcare, Brentford, UK; ¹⁴Global Research Strategy, ViiV Healthcare, Durham, NC, USA

MO42: Impact of switch towards 3TC/dolutegravir on the intact and total viral reservoir in the Rumba study

Evy Blomme¹, Wim Trypsteen¹, Mareva Delporte¹, Camilla Muccini², Evelien De Smet¹, Sophie Degroote³, Els Tobback³, Sophie Vanherrewege³, Els Caluwe³, Marie-Angélique De Scheerder³, Linos Vandekerckhove¹

¹Department of Internal Medicine and Pediatrics, HIV Cure Research Center, Ghent University, Ghent, Belgium; ²Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy; ³Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium

MO43: Prevalence, risk factors and the impact of antiretroviral treatment in SARS-CoV-2 infection in people with HIV: A cross-sectional study

Elisa de Lazzari¹, Jose L Blanco¹, Naira Rico², Xabier Filella², Natalia Egri³, Raquel Ruiz³, Maria A Marcos⁴, Maria del Mar Mosquera⁴, Jose Alcamí¹, Sonsoles Sánchez-Palomino¹, Carmen Hurtado¹, Cristina Rovira¹, Juan Ambrosioni¹, Ivan Chivite¹, Ana González-Cordón¹, Alexy Inciarte¹, Montserrat Laguno¹, Maria Martínez-Rebollar¹, Lorena de la Mora¹, Berta Torres¹, Esteban Martínez¹, Josep Mallolas¹, Jose M Miro¹

¹HIV Unit, Infectious Diseases Service, Hospital Clinic - August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain; ²Biochemistry Service, Biological Diagnostic Center, Hospital Clinic - August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain; ³Immunology Service, Biological Diagnostic Center, Hospital Clinic - August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain; ⁴Microbiology Service, Biological Diagnostic Center, Hospital Clinic - August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain



Oral Abstracts (continued)

Wednesday 26 October 2022 (continued)

MO44: Prevalence, outcomes, and factors associated with testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among people living with HIV across Europe in the multinational EuroSIDA cohort

Olga Fursa¹, Wendy Bannister¹, Bastian Neesgaard¹, Daria Podlekareva¹, Justyna Kowalska², Thomas Benfield³, Jan Gerstoft⁴, Joanne Reekie¹, Line D Rasmussen⁵, Inka Aho⁶, Giovanni Guaraldi⁷, Therese Staub⁸, Jose M Miro⁹, Jose M Laporte¹⁰, Daniel Elbirt¹¹, Tatiana Trofimova¹², Dalibor Sedlacek¹³, Raimonda Matulionyte¹⁴, Cristiana Oprea¹⁵, Vesna Hadziosmanović¹⁶, Amanda Mcroft¹, Lars Peters¹

¹Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, Copenhagen, Denmark; ²Department of Adults' Infectious Diseases, Medical University of Warsaw, Warsaw, Poland; ³Department of Infectious Diseases, Copenhagen University Hospital-Amager and Hvidovre, Hvidovre, Denmark; ⁴Department of Infectious Diseases Rigshospitalet, , Copenhagen, Denmark; ⁵Department of Infectious Diseases, Odense University Hospital, Odense, Denmark; ⁶Division of Infectious Diseases, Helsinki University Hospital, Helsinki, Finland; ⁷Modena HIV Cohort, Università degli Studi di Modena, Modena, Italy; ⁸Service des Maladies Infectieuses, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg; ⁹CIBERINFEC, Infectious Diseases Service, Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain; ¹⁰Servicio de Hospital a Domicilio, Hospital Universitario de Alava, Vitoria-Gasteiz, Spain; ¹¹Immunology and HIV Unit, Kaplan Medical Center, Allergy, Rehovot, Israel; ¹²HELPER, Novgorod Centre for AIDS Prevention and Control, Veliky Novgorod, Russian Federation; ¹³Department of Infectious Diseases, Charles University Hospital, Plzen, Czech Republic; ¹⁴Department of Infectious Diseases, Vilnius University, Faculty of Medicine, Vilnius, Lithuania; ¹⁵HIV Department, Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania; ¹⁶Infectious Diseases Clinic, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina

MO45: The stability and predictors of change in clinically relevant multimorbidity clusters over time among people with HIV in the Pharmacokinetic and clinical Observations in People over fifty (POPPY) study

Luxsena Sukumaran¹, Patrick WG Mallon², Frank A Post³, Memory Sachikonye⁴, Marta Boffito⁵, Jodi Meyerowitz⁶, Jaime Vera⁷, Ian Williams¹, Jane Anderson⁸, Margaret A Johnson⁹, Alan Winston¹⁰, Caroline A Sabin¹

¹Infection & Population Health, University College London, London, UK; ²School Of Medicine, University College Dublin, Dublin, UK; ³Inflammation Biology, School of Immunology & Microbial Sciences Kings College London, , London, UK; ⁴HIV i-Base, UK Community Advisory Board (UKCAB), London, UK; ⁵Faculty of Medicine Centre, Imperial College London, London, UK; ⁶UKCRC Clinical Trials Unit, Imperial College London, London, UK; ⁷Global Health and Infection, Brighton and Sussex Medical School, Brighton, UK; ⁸Centre for the Study of Sexual Health and HIV Homerton University Hospital NHS Foundation Trust, , London, UK; ⁹UCL Division of Medicine, Royal Free Hospital, London, UK; ¹⁰Department of Infectious Disease, Imperial College London, London, UK

MO46: Trends in maternal characteristics and pregnancy outcomes among women living with HIV in the UK: 2014 to 2019

Helen Peters, Laurette Bukasa, Kate Francis, Rebecca Sconza, Claire Thorne

UCL Great Ormond Street Institute of Child Health, Integrated Screening Outcomes Surveillance Service, London, UK

O41A: Perceptions and understandings of media and public health messaging about the monkeypox outbreak in the UK: Findings from a rapid response, co-produced survey

Sara Papparini¹, John Thornhill¹, Chikondi Mwendera¹, Sophie Strachan², Ryan Whitacre³, Will Nutland⁴, Chloe Orkin¹

¹SHARE Collaborative, Queen Mary University of London, London, UK; ²Sophia Forum, London, UK; ³Graduate Institute of International and Development Studies, Global Health Centre, Geneva, Switzerland; ⁴PrEPster/The Love Tank CIC, London, UK

and

O41B: Including women in the public health response to the monkeypox (MPXV) outbreak in the UK: Findings from a rapid response, co-produced survey

Sara Papparini¹, Sophie Strachan², John Thornhill³, Will Nutland⁴, Chikondi Mwendera³, Chloe Orkin³

¹Wolfson Institute of Population Health and SHARE Collaborative, Queen Mary University of London, London, UK; ²Sophia Forum, London, UK; ³Blizard Institute and SHARE Collaborative, Queen Mary University of London, London, UK;

⁴PrEPster/The Love Tank CIC, London, UK



Oral Abstracts (continued)

Wednesday 26 October 2022 (continued)

O42: Virological failure and HIV RNA re-suppression rates in four randomised trials of dolutegravir, efavirenz or protease inhibitor-based treatment in 3116 participants

Simiso Sokhela¹, Francois Venter¹, Bronwyn Bosch¹, Godspower Akpomiemie¹, Angela Tembo¹, Toby Pepperrell², Bryony Simmons³, Lloyd B Mulenga⁴, Alexandra Calmy⁵, Tamara Tovar Sanchez⁶, Eric Delaporte⁶, Carmen-Perez Casas⁷, Saye Khoo⁸, Helen Reynolds⁸, **Andrew Hill**⁹

¹Faculty of Health Sciences, Ezintsha, University of the Witwatersrand, Johannesburg, South Africa; ²School of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK; ³LSE Health, London School of Economics and Political Science, London, UK; ⁴Department of Medicine, University Teaching Hospital, Lusaka, Zambia; ⁵Division of Infectious Diseases, HIV-AIDS Unit, Geneva University Hospitals, Geneva, Switzerland; ⁶TransVIHMI, University of Montpellier, Montpellier, France; ⁷Global Health Campus, Unitaid, Le Grand-Saconnex, Switzerland; ⁸University of Liverpool, Department of Molecular and Clinical Pharmacology, Liverpool, UK; ⁹Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK

O43: Six-month outcomes of every 2-months long-acting cabotegravir and rilpivirine in a real-world setting: Effectiveness, adherence to injections and patient-reported outcomes from PLWHIV in the German CARLOS cohort

Jan Borch¹, Jenny Scherzer², **Celia Jonsson-Oldenbuettel**³, Gordon Weinberg⁴, Christoph Wyen⁵, Elena Rodriguez⁶, Stefan Scholten⁷, Samia Dakhia⁸, Kathrin Dymek², Bernd Westermayer⁹, Katharina Bernhardt²

¹Clinical Care, Praxis Goldstein, Berlin, Germany; ²Medical Affairs, ViiV Healthcare, Munich, Germany; ³Clinical Care, Medizinisches Versorgungszentrum München am Goetheplatz, Munich, Germany; ⁴Clinical Care, Infektiologisches Zentrum Steglitz, Berlin, Germany; ⁵Clinical Care, Praxis Ebertplatz, Cologne, Germany; ⁶Clinical Care Praxismgemeinschaft ViRo Schillerkiez, Berlin, Germany; ⁷Clinical Care, Praxis Hohenstaufenring, Cologne, Germany; ⁸Medical Affairs, ViiV Healthcare, Brentford, UK; ⁹Medical Affairs, GlaxoSmithKline GmbH, Munich, Germany

O44: Expanded multivariable models to assist patient selection for long-acting cabotegravir+rilpivirine treatment: Clinical utility of a combination of patient, drug concentration, and viral factors associated with virological failure over 152 weeks

Chloe Orkin¹, Jonathan M Schapiro², Carlo Federico Perno³, Daniel R Kuritzkes⁴, Parul Patel⁵, Rebecca DeMoor⁶, David Dorey⁷, Yongwei Wang⁸, Kelong Han⁹, Veerle Van Eygen¹⁰, Herta Crauwels¹¹, Susan L Ford¹², Christine L Latham¹³, Marty St Clair¹³, Joseph W Polli¹⁴, Simon Vanveggel¹⁵, Kati Vandermuelen¹⁶, Ronald D'Amico¹⁷, Harmony P Garges¹⁸, Andrew Zolopa¹⁹, William R Spreen¹⁷, Jean van Wyk²⁰, Amy G Cutrell²¹

¹Department of Immunobiology, Queen Mary University, London, UK; ²National Hemophilia Center, Sheba Medical Center, Ramat Gan, Israel; ³Microbiology and Diagnostic Immunology, Bambino Gesù Pediatric Hospital, Rome, Italy; ⁴Harvard Medical School, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; ⁵Global Medical Affairs, ViiV Healthcare, Durham, NC, USA; ⁶R&D Biostatistics, GSK, Collegeville, PA, USA; ⁷R&D Biostatistics, GSK, Mississauga, Canada; ⁸Biostatistics and Data Management, ViiV Healthcare Ltd, Durham, NC, USA; ⁹Clinical Pharmacology Modeling & Simulation, GSK, Collegeville, PA, USA; ¹⁰Clinical Microbiology and Immunology, Janssen Research & Development, Beerse, Belgium; ¹¹Clinical Pharmacology, Janssen Research & Development, Beerse, Belgium; ¹²Clinical Pharmacology, GSK, Durham, NC, USA; ¹³Translational Medicine Research, ViiV Healthcare Ltd, Durham, NC, USA; ¹⁴Scientific Communications and Medical Education, ViiV Healthcare Ltd, Durham, NC, USA; ¹⁵Statistics and Decision Sciences, Janssen Research & Development, Beerse, Belgium; ¹⁶Infectious Diseases, Janssen Research and Development, Beerse, Belgium; ¹⁷Research & Development, ViiV Healthcare Ltd, Durham, NC, USA; ¹⁸Global Medical, ViiV Healthcare Ltd, Durham, NC, USA; ¹⁹North America Medical Affairs, ViiV Healthcare Ltd, Durham, NC, USA; ²⁰Global Medical, ViiV Healthcare Ltd, Brentford, UK; ²¹Clinical Statistics, ViiV Healthcare Ltd, Durham, NC, USA

O45: Modeling and simulation to optimize islatravir once daily (QD) doses in HIV treatment naïve and virologically suppressed populations

Ryan Vargo¹, Seth Robey¹, Xiaowei Zang¹, Lihong Du¹, Jessica Roberts², Stephanie Klopfer¹, Todd Correll¹, Kathleen Squires¹

¹Merck & Co., Inc., Rahway NJ, USA; ²Simulation Plus, Cognigen Division, Buffalo, New York, USA



Oral Abstracts (continued)

Wednesday 26 October 2022 (continued)

O46: Total lymphocyte and CD4+ T-cell count changes in participants receiving islatravir (0.25, 0.75 and 2.25 mg QD) and doravirine +/- lamivudine: post-hoc analysis from a phase 2b dose- ranging study (P011)

Todd Correll¹, Jean-Michel Molina², Stephanie Klopfer¹, Anjana Grandhi¹, Rima Lahoulou³, Yun-Ping Zhou¹, Karen Eves¹, Kathleen Squires¹

¹Merck & Co., Inc., Rahway NJ, USA; ²University of Paris, St-Louis and Lariboisière Hospitals, Paris, France; ³MSD France, Puteaux, France